Business Description

Exicure Inc
NAICS : 325411
SIC : 2834
ISIN : US30205M1018
Compare
Compare
Traded in other countries / regions
XCUR.USA2H0A.Germany IPO Date
2018-05-09Description
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.72 | |||||
Debt-to-EBITDA | 1.39 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -11.93 | |||||
Beneish M-Score | 12.65 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 110 | |||||
3-Year EPS without NRI Growth Rate | 65.6 | |||||
3-Year Book Growth Rate | -52.6 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.77 | |||||
9-Day RSI | 37.04 | |||||
14-Day RSI | 39.06 | |||||
6-1 Month Momentum % | -13.96 | |||||
12-1 Month Momentum % | -49.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.56 | |||||
Quick Ratio | 2.56 | |||||
Cash Ratio | 1.63 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.1 | |||||
Shareholder Yield % | 57.25 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 13.48 | |||||
Net Margin % | 12.88 | |||||
ROE % | 41.75 | |||||
ROA % | 11.72 | |||||
ROIC % | 14.46 | |||||
ROC (Joel Greenblatt) % | 32.68 | |||||
ROCE % | 20.58 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 0.45 | |||||
PE Ratio without NRI | 0.45 | |||||
PS Ratio | 0.17 | |||||
PB Ratio | 0.67 | |||||
Price-to-Tangible-Book | 0.67 | |||||
EV-to-EBIT | 3.38 | |||||
EV-to-EBITDA | 2.2 | |||||
EV-to-Revenue | 0.47 | |||||
EV-to-FCF | -0.52 | |||||
Price-to-Graham-Number | 0.12 | |||||
Earnings Yield (Greenblatt) % | 29.59 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XCUR
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Exicure Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 23.79 | ||
EPS (TTM) ($) | 1.68 | ||
Beta | 0.78 | ||
Volatility % | 80.5 | ||
14-Day RSI | 39.06 | ||
14-Day ATR ($) | 0.088445 | ||
20-Day SMA ($) | 0.84453 | ||
12-1 Month Momentum % | -49.01 | ||
52-Week Range ($) | 0.63 - 1.96 | ||
Shares Outstanding (Mil) | 8.65 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Exicure Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Exicure Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Exicure Inc Frequently Asked Questions
What is Exicure Inc(XCUR)'s stock price today?
The current price of XCUR is $0.75. The 52 week high of XCUR is $1.96 and 52 week low is $0.63.
When is next earnings date of Exicure Inc(XCUR)?
The next earnings date of Exicure Inc(XCUR) is 2023-11-18 Est..
Does Exicure Inc(XCUR) pay dividends? If so, how much?
Exicure Inc(XCUR) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |